Companies /Healthcare

Boston Scientific Corp

NYSE: BSX Medical Devices
$48.30
â–² $1.46 (+3.12%) today
Markets closed · 7:22pm ET

Q3 2025 Earnings

Reported Oct 22, 2025, 6:32am ET · SEC source
$0.75
Beat +5.63%
EPS · est. $0.71
$5.1B
Beat +1.83%
Revenue · est. $5.0B
−5.4%
Trailing market
BSX vs S&P since report
6 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−6%−3%0Oct 22Oct 23report 6:32am ETearnings−0.2%−0.3%
−6%−3%0Oct 22Oct 23earnings−0.2%−0.3%
BSX −0.3%S&P 500 −0.2%
−6%−3%0Oct 22Oct 23report 6:32am ETearnings−0.3%−0.3%
−6%−3%0Oct 22Oct 23earnings−0.3%−0.3%
BSX −0.3%NASDAQ −0.3%
0+3%+6%Oct 21Oct 29report 6:32am ETearnings+2.1%+2.3%
0+3%+6%Oct 21Oct 29earnings+2.1%+2.3%
BSX +2.3%S&P 500 +2.1%
0+3%+6%Oct 21Oct 29report 6:32am ETearnings+3.8%+2.3%
0+3%+6%Oct 21Oct 29earnings+3.8%+2.3%
BSX +2.3%NASDAQ +3.8%
+3.95%
Day of report
−1.41%
Next session
−3.42%
One week
−6.71%
30 days

S&P 500 over the same 30 days: −1.31%.

Did BSX Beat Earnings? Q3 2025 Results

Boston Scientific delivered a standout third quarter for fiscal 2025, posting adjusted EPS of $0.75 and revenue of $5.07 billion, beating consensus estimates of $0.71 and $4.97 billion by 5.09% and 1.83%, respectively, while revenue climbed 20.3% year over year and topped the company's own guidance range. The primary engine behind the quarter's strength was the Cardiovascular segment, where Cardiology sales of $2.64 billion grew 24.0% on a reported basis, fueled by the continued global rollout of the FARAPULSE pulsed field ablation system, including expanded labeling in Japan; electrophysiology sales alone surged 63% in the quarter, reinforcing the company's momentum in pulsed field ablation technology. The U.S. led geographically with $3.29 billion in sales, up 27.0%, while EMEA lagged at just 2.6% reported growth. Looking ahead, Boston Scientific guided Q4 adjusted EPS to $0.77 to $0.79 and full-year 2025 adjusted EPS to $3.02 to $3.04, with organic revenue growth of approximately 15.5% expected for the full year.

Key Takeaways
  • Cardiovascular segment organic growth of 19.4% driven by strong Cardiology performance
  • U.S. region grew 27.0% driving majority of overall growth
  • FARAPULSE pulsed field ablation system continued global expansion
  • Urology growth of 28.1% boosted by acquisitions

“We delivered another exceptional quarter of strong performance across businesses and regions thanks to the winning spirit of our global team.”

Boston Scientific CEO, on the earnings call

Forward Guidance & Outlook

For Q4 2025, Boston Scientific estimates net sales growth of 14.5-16.5% on a reported basis and 11-13% on an organic basis versus the prior year. Q4 GAAP EPS is estimated at $0.48 to $0.52 and adjusted EPS at $0.77 to $0.79. For the full year 2025, the company estimates approximately 20% reported net sales growth and approximately 15.5% organic growth, with GAAP EPS of $1.97 to $2.01 and adjusted EPS of $3.02 to $3.04.

BSX YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$0$2.0B$4.0B$4.2B$5.1BRevenue$2.6B$3.5BGross Profit$674.0M$1.0BOperating Income$469.0M$755.0MNet Income
$0$2.0B$4.0BRevenueGross ProfitOperating IncomeNet Income

BSX Revenue by Segment

Cardiovascular$3.3B+22.4%
Cardiology$2.6B+24.0%
MedSurg$1.7B+16.4%
Endoscopy$747.0M+10.1%
Urology$682.0M+28.1%
Peripheral Interventions$702.0M+16.7%
Neuromodulation$293.0M+9.1%

BSX Revenue by Geography

United States$3.3B+27.0%
EMEA$793.0M+2.6%
Asia Pacific$802.0M+17.1%
Latin America$175.0M+10.4%

Figures from SEC filings and company reports. Not investment advice.